Drug
Hormone Therapy
CI-DRUG-00000281Explore in graph →NCIt C15445 CIViC
Regulatory
Approvals (0)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
Data not yet available
No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.
What CancerIndex knows
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Phase4 | Phase 4 | 39 | 17 | 23 | 66 | 0 | — | — | 1989-05 |
| Malignant Breast Neoplasm | Phase3 | Phase 3 | 21 | 11 | 11 | 36 | 0 | — | — | 1989-05 |
| Malignant Prostate Neoplasm | Phase3 | Phase 3 | 4 | 1 | 5 | 9 | 0 | — | — | 2003-06 |
ComputedclinicaltrialsProvenance
- Source
- clinicaltrials
- Layer
- derived (computed by CancerIndex)
Curated evidence
Clinical evidence (5)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24185512
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ESR1 D538G1 | ||||||||
| Hormone Therapy | Malignant Breast Neoplasm | |||||||
Clinical trials
Trials with this intervention (73)
Most recently updated first, 50 per page.
clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04923542 | SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases | recruiting | Phase 1 / Phase 2 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844759 | SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers(SOLIS) |